C H Adler1, T G Beach2, H A Shill3, J N Caviness1, E Driver-Dunckley1, M N Sabbagh3, A Patel1, L I Sue2, G Serrano2, S A Jacobson4, K Davis4, C M Belden4, B N Dugger2,5, S A Paciga6, A R Winslow6, W D Hirst6, J G Hentz7. 1. Department of Neurology, Parkinson's Disease and Movement Disorders Center, Mayo Clinic Arizona, Scottsdale, AZ, USA. 2. Civin Laboratory for Neuropathology, Banner Sun Health Research Institute, Sun City, AZ, USA. 3. Barrow Neurological Institute, Phoenix, AZ, USA. 4. Cleo Roberts Center, Banner Sun Health Research Institute, Sun City, AZ, USA. 5. University of California, San Francisco, CA, USA. 6. Pfizer Neuroscience Research Unit, Cambridge, MA, USA. 7. Department of Biostatistics, Mayo Clinic Arizona, Scottsdale, AZ, USA.
Abstract
BACKGROUND AND PURPOSE: Mutations in the glucocerebrosidase (GBA) gene are known to be a risk factor for Parkinson's disease (PD). Data on clinicopathological correlation are limited. The purpose of this study was to determine the clinicopathological findings that might distinguish PD cases with and without mutations in the GBA gene. METHODS: Data from the Arizona Study of Aging and Neurodegenerative Disorders were used to identify autopsied PD cases that did or did not have a GBA gene mutation. Clinical and neuropathological data were compared. RESULTS: Twelve PD cases had a GBA mutation and 102 did not. The GBA mutation cases died younger (76 vs. 81 years of age) but there was no difference in disease duration or clinical examination findings. No neuropathological differences were found in total or regional semi-quantitative scores for Lewy-type synucleinopathy, senile plaques, neurofibrillary tangles, white matter rarefaction or cerebral amyloid angiopathy scores. CONCLUSIONS: In longitudinally assessed, autopsied PD cases, those with GBA mutations had a younger age at death but there was no evidence for clinical or neuropathological differences compared to cases without GBA mutations. Due to the small GBA group size, small differences cannot be excluded.
BACKGROUND AND PURPOSE: Mutations in the glucocerebrosidase (GBA) gene are known to be a risk factor for Parkinson's disease (PD). Data on clinicopathological correlation are limited. The purpose of this study was to determine the clinicopathological findings that might distinguish PD cases with and without mutations in the GBA gene. METHODS: Data from the Arizona Study of Aging and Neurodegenerative Disorders were used to identify autopsied PD cases that did or did not have a GBA gene mutation. Clinical and neuropathological data were compared. RESULTS: Twelve PD cases had a GBA mutation and 102 did not. The GBA mutation cases died younger (76 vs. 81 years of age) but there was no difference in disease duration or clinical examination findings. No neuropathological differences were found in total or regional semi-quantitative scores for Lewy-type synucleinopathy, senile plaques, neurofibrillary tangles, white matter rarefaction or cerebral amyloid angiopathy scores. CONCLUSIONS: In longitudinally assessed, autopsied PD cases, those with GBA mutations had a younger age at death but there was no evidence for clinical or neuropathological differences compared to cases without GBA mutations. Due to the small GBA group size, small differences cannot be excluded.
Authors: Thomas G Beach; Charles H Adler; Lucia I Sue; Geidy Serrano; Holly A Shill; Douglas G Walker; LihFen Lue; Alex E Roher; Brittany N Dugger; Chera Maarouf; Alex C Birdsill; Anthony Intorcia; Megan Saxon-Labelle; Joel Pullen; Alexander Scroggins; Jessica Filon; Sarah Scott; Brittany Hoffman; Angelica Garcia; John N Caviness; Joseph G Hentz; Erika Driver-Dunckley; Sandra A Jacobson; Kathryn J Davis; Christine M Belden; Kathy E Long; Michael Malek-Ahmadi; Jessica J Powell; Lisa D Gale; Lisa R Nicholson; Richard J Caselli; Bryan K Woodruff; Steven Z Rapscak; Geoffrey L Ahern; Jiong Shi; Anna D Burke; Eric M Reiman; Marwan N Sabbagh Journal: Neuropathology Date: 2015-01-26 Impact factor: 1.906
Authors: Thomas G Beach; Charles H Adler; LihFen Lue; Lucia I Sue; Jyothi Bachalakuri; Jonette Henry-Watson; Jeanne Sasse; Sarah Boyer; Scophil Shirohi; Reed Brooks; Jennifer Eschbacher; Charles L White; Haru Akiyama; John Caviness; Holly A Shill; Donald J Connor; Marwan N Sabbagh; Douglas G Walker Journal: Acta Neuropathol Date: 2009-04-28 Impact factor: 17.088
Authors: Karen E Murphy; Amanda M Gysbers; Sarah K Abbott; Nahid Tayebi; Woojin S Kim; Ellen Sidransky; Antony Cooper; Brett Garner; Glenda M Halliday Journal: Brain Date: 2014-01-28 Impact factor: 13.501
Authors: Matthew E Gegg; Derek Burke; Simon J R Heales; J Mark Cooper; John Hardy; Nicholas W Wood; Anthony H V Schapira Journal: Ann Neurol Date: 2012-09 Impact factor: 10.422
Authors: Diana A Olszewska; Allan McCarthy; Alexandra I Soto-Beasley; Ronald L Walton; Brian Magennis; Russell L McLaughlin; Orla Hardiman; Owen A Ross; Tim Lynch Journal: Front Neurol Date: 2020-06-30 Impact factor: 4.003
Authors: Melissa Leija-Salazar; Fritz J Sedlazeck; Marco Toffoli; Stephen Mullin; Katya Mokretar; Maria Athanasopoulou; Aimee Donald; Reena Sharma; Derralynn Hughes; Anthony H V Schapira; Christos Proukakis Journal: Mol Genet Genomic Med Date: 2019-01-13 Impact factor: 2.183
Authors: Farzaneh Atashrazm; Deborah Hammond; Gayathri Perera; Carol Dobson-Stone; Nicole Mueller; Russell Pickford; Woojin Scott Kim; John B Kwok; Simon J G Lewis; Glenda M Halliday; Nicolas Dzamko Journal: Sci Rep Date: 2018-10-18 Impact factor: 4.379